EXECUTIVE SUMMARY
Transpl. Int.
4th workshop purification therapies, from research to clinics “the end of the beginning”: executive summary
- MA
Mauro Atti 1
- GR
Giuseppe Remuzzi 2
- FG
Feltrin Giuseppe 3
- GC
Gabriel C Oniscu 4
- RP
Robert Porte 5
- MR
Marco Ranieri 6
- MR
Mauro Rinaldi 7
- JL
Jean Louis Vincent 8
1. Aferetica Srl, Bologna, Italy
2. Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
3. National Transplant Center, National Institute of Health (ISS), Rome, Italy
4. Karolinska Institutet (KI), Huddinge, Sweden
5. Erasmus MC Transplant Institute, Dept. of Surgery, Erasmus University Medical Center, Rotterdam, Netherlands
6. Universita degli Studi di Bari Aldo Moro, Bari, Italy
7. Cardiac Surgery Division, Department of Surgical Sciences, Città della Salute e della Scienza University Hospital, University of Turin, Turin, Italy
8. Hôpital Erasme- Cliniques universitaires de Bruxelles, Université libre de Bruxelles, Brussels, Belgium
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Abstract
Over recent decades, advances in medicine have transformed the management of systemic diseases, severe inflammatory syndromes, and end-stage organ failure, expanding therapeutic possibilities in intensive care and transplantation. The fourth Workshop on Purification Therapies (WPT25), entitled "From Research to Clinic: The End of the Beginning", marked an important moment in the maturation of extracorporeal blood purification therapies (EBPTs) and organ perfusion technologies. The first day focused on dysregulated inflammatory diseases and EBPTs, highlighting the role of inflammatory mediators as cytokines, pointed out the potentiality in their clinical applications in septic and cardiogenic shock. The discussion was focused on patient selection, timing, dosing, and drug–device interactions. The second day addressed organ preservation and regeneration, emphasizing in situ and ex situ perfusion strategies to expand donor eligibility—including DCD and extended criteria donors—while mitigating the iatrogenic effects as the ischemia–reperfusion injury. Discussions explored temperature management, inflammatory modulation during procurement and treatment, and future perspectives such as personalized perfusion protocols and xenotransplantation. With 550 participants, 26 oral presentations, practical workshops, and 161 scientific contributions published in one special issue of Transplant International, the meeting consolidated evidence and try to define priorities for integrating purification and perfusion therapies into clinical practice.
Summary
Keywords
blood purification, cytokines adsorption, ex-situ perfusion, organ regeneration, perfusion machines
Received
02 April 2026
Accepted
07 May 2026
Copyright
© 2026 Atti, Remuzzi, Giuseppe, Oniscu, Porte, Ranieri, Rinaldi and Vincent. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Mauro Atti, mauro.atti@aferetica.com
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.